MedAssets reiterates guidance for FY12 adjusted EPS $1.10 at midpoint Consensus $1.12. Reiterates view of FY12 revenue $635.0M at midpoint, consensus $636.2M. Says consolidated net revenue guidance increased by about 1.5% following its Q3 report based on nine]month 2012 performance and visibility through remainder of year. Says YTD 2012 results ahead of its expectations. Guidance and comments from presentation slides for J.P. Morgan Healthcare Conference.
Healthways, MedAssets partner in new five-year agreement Healthways (HWAY) has partnered with MedAssets (MDAS) to expand patient access to the Dr. Dean Ornish Program for Reversing Heart Disease. Under the five-year agreement, Healthways has contracted with MedAssets as its sales partner to accelerate deployment of the Ornish Reversal Program to hospitals, health systems and physician organizations. The Ornish Reversal Program is the most scientifically proven platform in lifestyle medicine for treating and reversing heart disease and other chronic conditions.